(2-chloro-7(9)H-purin-6-yl)-(4-nitro-phenyl)-amine | 39639-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2-chloro-7(9)H-purin-6-yl)-(4-nitro-phenyl)-amine
• 英文别名: 2-chloro-6-(4-nitro-phenyl-amino)-purine；2-chloro-N-(4-nitrophenyl)-7H-purin-6-amine
• CAS: 39639-50-4
• 化学式: C₁₁H₇ClN₆O₂
• 分子量: 290.669
• InChiKey: DVBLPVYJSAJOFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-羟乙基哌嗪 、 (2-chloro-7(9)H-purin-6-yl)-(4-nitro-phenyl)-amine 在 sodium tetrahydroborate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.08h， 生成 N-(4-nitrophenyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-9H-purin-6-amine
  参考文献：
  名称：

  Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase

  摘要：

  We report here the discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase by adopting a strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and bioassay. Thirty two compounds were selected and synthesized. All compounds showed potent inhibitory activity against c-Src kinase with IC50 values ranging from 3.14 mu M to 0.02 mu M. Compound 5i was identified as one of the most potent agent with an IC50 120 times lower than those of the hits. The high hit rate (100%) and the potency of the new Src kinase inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening. The novel active chemical entities reported here should be good leads for further development of purine-based anticancer drugs targeting Src tyrosine kinase. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.032
• 作为产物：
  描述：

  4-硝基苯胺 、 2,6-二氯嘌呤 以 DMF n-butanol 为溶剂， 反应 24.0h， 以2-Chloro-6-(4-nitro-phenyl-amino)-purine is obtained的产率得到(2-chloro-7(9)H-purin-6-yl)-(4-nitro-phenyl)-amine
  参考文献：
  名称：

  Purine derivatives and processes for their preparation

  摘要：

  描述了公式1中符号定义如权利要求1所述的2-氨基-6-苯胺基嘌呤衍生物。这些化合物抑制p34cdc2 / cyclin Bcdc13激酶，可用于治疗过度增殖性疾病，例如肿瘤疾病。

  公开号：

  US07091346B1

文献信息

• [EN] PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION<br/>[FR] DERIVES PURINES ET PROCEDES DE PREPARATION ASSOCIES
  申请人：NOVARTIS AG

  公开号：WO1997016452A1

  公开（公告）日：1997-05-09

  (EN) 2-Amino-6-anilino-purine derivatives of formula (1) in which the symbols are as defined in claim 1, are described. These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and can be used for treatment of hyperproliferative diseases, for example tumour diseases.(FR) On décrit des dérivés 2-amino-6-anilino-purines de la formule 1 dans laquelle les symboles sont tels que définis dans la revendication 1. Ces composés inhibent la p34cdc2/cycline Bcdc13 kinase et on peut les utiliser dans le traitement de maladies à hyperprolifération, par exemple des tumeurs.

  (中文) 描述了式（1）中符号如权利要求1所定义的2-氨基-6-苯胺基嘌呤衍生物。这些化合物抑制p34cdc2 / cyclin Bcdc13激酶，可用于治疗增生性疾病，例如肿瘤疾病。
• Purine derivatives and processes for their preparation
  申请人：Novartis AG

  公开号：US07091346B1

  公开（公告）日：2006-08-15

  2-Amino-6-anilino-purine derivatives of the formula 1 in which the symbols are as defined in claim 1 are described. These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and can be used for treatment of hyperproliferative diseases, for example tumour diseases.

  描述了公式1中符号定义如权利要求1所述的2-氨基-6-苯胺基嘌呤衍生物。这些化合物抑制p34cdc2 / cyclin Bcdc13激酶，可用于治疗过度增殖性疾病，例如肿瘤疾病。
• PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION
  申请人：Novartis AG

  公开号：EP0874846B1

  公开（公告）日：2003-04-02
• US7091346B1
  申请人：——

  公开号：US7091346B1

  公开（公告）日：2006-08-15
• Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase
  作者：He Huang、Jingui Ma、Jianmei Shi、Linghua Meng、Hualiang Jiang、Jian Ding、Hong Liu

  DOI：10.1016/j.bmc.2010.05.032

  日期：2010.7

  We report here the discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase by adopting a strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and bioassay. Thirty two compounds were selected and synthesized. All compounds showed potent inhibitory activity against c-Src kinase with IC50 values ranging from 3.14 mu M to 0.02 mu M. Compound 5i was identified as one of the most potent agent with an IC50 120 times lower than those of the hits. The high hit rate (100%) and the potency of the new Src kinase inhibitors demonstrated the efficiency of the strategy for the focused library design and virtual screening. The novel active chemical entities reported here should be good leads for further development of purine-based anticancer drugs targeting Src tyrosine kinase. (C) 2010 Elsevier Ltd. All rights reserved.